Core Viewpoint - The company plans to repurchase shares with an amount ranging from RMB 25 million to RMB 50 million to maintain company value and shareholder rights [1][3][4] Summary by Sections Repurchase Plan Details - The repurchase amount will not be less than RMB 25 million and not exceed RMB 50 million [1][4] - The funding source for the repurchase will be entirely from self-owned or self-raised funds, including special loans for stock repurchase [1][8] - The maximum repurchase price is set at RMB 32.44 per share, which does not exceed 130% of the average trading price over the last 30 trading days prior to the board's decision [1][4][6] - The repurchase will be conducted through centralized bidding and is expected to be completed within three months from the board's approval [1][5][6] Purpose and Use of Repurchased Shares - The repurchased shares will be used to maintain company value and shareholder rights, and will be sold within 12 months after the repurchase results are disclosed [1][4][13] - If the company fails to sell the shares within the stipulated time, the unsold shares will be canceled [1][4][13] Shareholder and Management Plans - The controlling shareholders and key management personnel have no plans to reduce their holdings during the repurchase period and the following three to six months [2][12] - The financial officer indicated a potential for share reduction in the future, subject to legal requirements [2][12] Implementation and Regulatory Compliance - The repurchase plan was approved by the board on June 26, 2025, and does not require further shareholder approval [3][4] - The company will adjust the repurchase terms in accordance with any changes in national policies [1][4][15] - The company has obtained a loan commitment from a bank to support the repurchase [8][10] Financial Impact - The repurchase amount will represent approximately 0.38% to 0.76% of the total share capital, depending on the final number of shares repurchased [6][7] - The total assets of the company as of March 31, 2025, were RMB 775.92 million, with a net asset value of RMB 652.18 million, indicating that the repurchase will not significantly impact the company's financial stability [10][11]

证券代码：688298 证券简称：东方生物 公告编号：2025-030 浙江东方基因生物制品股份有限公司 会议由监事方晓萍女士主持召开，全体与会监事经认真审议和表决，形成以 下决议： 1、审议通过《关于以集中竞价交易方式回购公司股份的方案》 表决结果：本议案有效表决票 3 票，3 票同意，0 票反对，0 票弃权。 公司监事会认为：本次公司使用不低于人民币 2,500 万元（含），不超过人 民币 5,000 万元（含）的自有资金或自筹资金（含股票回购专项贷款资金等）， 以集中竞价交易方式回购公司股份，回购期限为自董事会审议通过本次股份回购 方案之日起不超过 3 个月。符合《上市公司股份回购规则》《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等法律法规、规范性文件的有关规定， 符合公司全体股东利益，不存在损害公司及股东尤其是中小股东利益的情形，该 议案的审议程序合法合规。公司监事会同意本次以集中竞价交易方式回购公司股 份的事项。 具体内容详见公司于同日在上海证券交易所网站(http://www.sse.com.cn) 披露的《关于以集中竞价交易方式回购公司股份的方案》（公告编号 2025-028） ...

证券代码：688298 证券简称：东方生物 公告编号：2025-029 表决情况：同意 7 票、反对 0 票、弃权 0 票。 具体内容详见公司于同日在上海证券交易所网站(http://www.sse.com.cn) 披露的《关于以集中竞价交易方式回购股份的方案》（公告编号 2025-028）。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"公司"）第三届董事会第 十三次会议于 2025 年 6 月 23 日以电子邮件的形式发出会议通知，于 2025 年 6 月 26 日上午 9:00 在公司会议室以现场会议加通讯表决的方式召开。会议应出席 董事 7 名，实到出席董事 7 名。会议召开符合法律法规、《公司法》及《公司章 程》的相关规定。 会议由董事长方剑秋先生主持召开，全体与会董事经认真审议和表决，形成 以下决议： 1、审议通过《关于以集中竞价交易方式回购公司股份的方案》 董事会同意公司使用不低于人民币 2,500 万元（含），不超过人民币 5,000 万元（含）的自 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-028 浙江东方基因生物制品股份有限公司 关于以集中竞价方式回购公司股份的方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 2,500 万元（含），不超过人民币 5,000 万元（含）； ● 回购股份资金来源：本次回购股份的资金来源全部为自有资金或自筹资金（含 股票回购专项贷款资金等）； ● 回购股份用途：本次回购的股份将用于维护公司价值及股东权益，将在公司披 露回购结果暨股份变动公告 12 个月后采用集中竞价交易方式出售，并在 3 年内完 成出售。公司如未能在规定期限内完成出售，未出售部分将履行相关程序予以注 销。如国家对相关政策作调整，则本回购方案按调整后的政策实行； ● 回购股份价格：不超过 32.44 元，该价格未超过董事会通过回购股份决议前 30 个交易日公司股票交易均价的 130%； ● 回购股份方式：以集中竞价的方式； ● 回购股份期限：自董事会审议通过本次股份回购方案之日起不超过 3 个月； ...

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

证券代码：688298 证券简称：东方生物 公告编号：2025-027 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 三、对上市公司的影响 全自动免疫印记分析仪主要用于过敏源检测试剂、自免检测试剂等配套使用。 PSA证书的取得，进一步丰富了公司在欧盟肿瘤标志物检测领域的技术路径及 产品系列，主要用于前列腺癌的检测和患者筛查、复发检测、诊断后监测和治疗 监测等管理。 上述产品的取证有利于国内外市场的整体拓展。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 及子公司杭州深度生物科技有限公司近日取得以下医疗器械注册证（体外诊断试 剂），相关证书内容公告如下： 一、中国医疗器械注册取证主要内容如下： | 产品名称 | 证书编号 | 预期用途 | 有效期 | 持证主体 | | --- | --- | --- | --- | --- | | 全自动免疫印迹分析仪 | 浙械注准 20252221447 | 基于免疫印迹原理，与适配测 试剂配合 ...

Core Viewpoint - A total of 14 listed companies announced share buybacks or increases in shareholdings this week, with significant involvement of loans for these activities [1][2]. Group 1: Companies Announcing Buybacks or Increases - Kailong High-Tech plans to repurchase shares worth between 25 million to 50 million yuan, with a loan of 25 million yuan [2]. - Hunan Haili intends to repurchase between 8.38 million to 16.76 million shares, supported by a loan of 200 million yuan [2]. - Guangda Special Materials aims to repurchase shares worth between 200 million to 400 million yuan, with a loan not exceeding 360 million yuan [2]. - Dahao Technology's controlling shareholder plans to increase shareholdings by 50 million to 100 million yuan [2]. - Qianhong Pharmaceutical's actual controller intends to continue increasing holdings by no less than 12.4 million shares [2]. - Bluetian Gas's controlling shareholder plans to increase holdings by 100 million to 150 million yuan, with a loan not exceeding 135 million yuan [2]. - Aikedi plans to repurchase shares worth between 100 million to 200 million yuan [2]. - Sichuan Changhong intends to repurchase shares worth between 250 million to 500 million yuan, with a loan not exceeding 450 million yuan [2]. - Qizhong Technology plans to repurchase shares worth between 75 million to 150 million yuan [2]. - Oriental Bio's chairman proposed a repurchase of shares not exceeding 50 million yuan [2]. - Yunlu Co. plans for directors and senior management to collectively increase holdings by 4 million to 12 million yuan [2]. - Hongli Zhihui's controlling shareholder plans to increase holdings by 25 million to 50 million yuan, with a loan not exceeding 45 million yuan [2]. - Dongfang Shenghong's controlling shareholder intends to increase holdings by 500 million to 1 billion yuan, with a loan not exceeding 900 million yuan [2]. - Midea Group plans to repurchase shares worth between 5 billion to 10 billion yuan, with a loan not exceeding 9 billion yuan [2].

Core Viewpoint - The company, Zhejiang Oriental Gene Biotech Co., Ltd., reported a slight increase in revenue for 2024, but a significant loss in net profit, primarily due to a decline in domestic sales and a contrasting increase in international sales [1][2]. Revenue Analysis - The company's total revenue for 2024 was 828 million yuan, a year-on-year increase of 0.95%, while the net profit attributable to shareholders was -529 million yuan, a year-on-year increase in loss of 33.06% [1]. - Domestic revenue was 207 million yuan, a decline of 35.7%, while international revenue reached 605 million yuan, an increase of 23.14% [1][2]. - The overall product sales volume decreased by 16.1% in 2024 [1]. Product Sales Breakdown - Domestic sales were primarily from the infectious disease testing series, which accounted for 39.52% of domestic revenue, but saw a volume decrease of 21.70% [1]. - The COVID-19 testing series generated 55.33% of domestic revenue but experienced a significant volume decline of 75.37% [1]. - Internationally, the drug testing series accounted for 49.67% of revenue, with a slight increase in sales volume [1][2]. Customer Analysis - The top domestic customers included new clients from trade and existing clients in infectious disease testing, with significant fluctuations in sales due to the COVID-19 product line [2]. - Internationally, major clients included large chain pharmacies in the U.S. and new clients in Mexico, contributing to the overall revenue growth [2][3]. Cost and Profit Margin - The company's operating costs for 2024 were 554 million yuan, an increase of 21.26%, with direct materials and manufacturing costs rising by 15.91% and 54.36%, respectively [5]. - The gross profit margins for domestic and international sales were 54.26% and 24.07%, respectively, both showing a decline compared to the previous year [5][6]. Market Dynamics - The decline in domestic sales was attributed to a significant drop in COVID-19 product sales, while international sales benefited from acquisitions and new product launches [3][5]. - The company expanded its market presence in Africa and introduced new online sales models, contributing to the increase in international revenue [3][4].

证券代码：688298 证券简称：东方生物 公告编号：2025-025 浙江东方基因生物制品股份有限公司 关于董事长提议回购公司部分股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"本公司"或"公司"）于 2025年6月17日收到公司董事长方剑秋先生（以下简称"提议人"）《关于提议 浙江东方基因生物制品股份有限公司回购公司部分股份的函》，具体内容如下： 一、提议人的基本情况及提议时间 1、提议人：公司董事长方剑秋先生 2、提议时间：2025 年 6 月 17 日 二、提议回购股份的原因和目的 本着增强投资者信心，稳定及提升公司价值，以及对公司未来发展的信心， 公司董事长方剑秋先生提议公司通过集中竞价交易方式回购部分公司股份，将用 于维护公司价值及股东权益。 上述回购股份的用途符合《上海证券交易所上市公司自律监管指引第 7 号— —回购股份》第二条第（四）项第一款所指情形：公司股票收盘价格低于最近一 期每股净资产。 三、提议内容 1、回购股份的种类：公司发行的人民币 ...

浙江东方基因生物制品股份有限公司 关于上海证券交易所对公司 2024 年年度报告 信息披露监管问询函的回复 证券代码：688298 证券简称：东方生物 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"、"公司"、 "本公司"）于近日收到上海证券交易所《关于浙江东方基因生物制品股份有限 公司 2024 年年度报告的信息披露监管问询函》（上证科创公函【2025】0152 号）， 现将问询函的相关问题做如下补充说明： 一、关于营业收入。公司主营业务为体外诊断试剂。2024 年，公司营业收 入为 8.28 亿元，同比增长 0.95%，归母净利润为-5.29 亿元，同比增亏 33.06%。 其中，境外收入 6.05 亿元，同比增长 23.14%；境内收入 2.07 亿元，同比下 滑 35.7%。公司 2024 年产品销量同比减少 16.1%。公司综合毛利率同比减少 12 个百分点。 请公司：（1）列示 2024 年境内主要销售产品类型、用途、收入金额、 ...